Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Investor Presentation (February 2006)
19 slides from Pyc Therapeutics's investor presentation, Feb 3, 2006
Slide 1: Dr Stewart Washer, Chief Executive Officer
Dr Stewart Washer Chief Executive Officer February, 2006
Slide 2: Major Shareholders
Major Shareholders Biotech Capital Ltd: . 26.9% Institute for Child Research: 19.0% ~Dr-Paul Watt. -: ; 3.7% Share Price and Volume Past 6 months OND BA pODIES
Slide 3: Recent Events
Recent Events i LE. 7 7 . aye 7 oke trials positive in rat model |. HYLOGICA FOND BNIB ODIES
Slide 4: Investing in PYC: Technology and Market
wvestin PYC?. ._ Technology and Market io in inflammatory diseases burns and stroke ets with unmet needs ology (Phylomers®) value yond antibodies, US$11bn drug rope.and Australia/NZ... 2 months to significantly re-tate stock S) preclinical data and partn PYC35B -and partneri ng deal nt interest g di
Slide 5: DAM B
DAM BODIES
Slide 6: Milestone payments, royalties
ilestone payments, royalties ill be undertaken where a_clie a number. fin revenue See HYLOGICA MD BAT ODIES
Slide 7: Drug Pipeline
Drug Pipeline Collaborators BURN TREATMENT PHEUMATOND ae y : joven ARTURUIS | ® ANRI 23... ~--© Mimotopes ae ~-Axela Biosensors Dual Systems AG 8 Uni of Melbourne ot . LERONES COLITIS IRRITABLE 2 eee Gower. ve ; PS TE SYNDROME THAUIMA PHYLOGICA DAM BODIES
Slide 8: Mechanism of Action
anism of Action DAM BODIES
Slide 9: Commercial Proposition
jmmercial Proposition beyond antibodies ( duced costs) potential (Patient Friendly) tack (More Profits) @ can be used for disease targ intioodies cannot penetrate cells) HY LOG ICA TOMD Ba BOUIES
Slide 10: Impairment of function (penumbra)
Impairment of function (penumbra) : Structural lesion i Minutes OND BA pODIES
Slide 11: Stroke and Alzheimer model results
6S completely prevented -° & ells in stroke and Alzheimer model al global brain damage-model - immunogenicity and affinity was all OND BA pODIES
Slide 12: Leading cause of accidental injury
d leading cause of accidental ells surrounding the injury. site ilar to the damage following a - MD BAT ODIES
Slide 13: Burns
Burns idate PYC35B has demonstrated I model : HYLOGICA MD BAT ODIES
Slide 14: Treatments represent significant advantages
atments represent significant / current therapies, ed cost of goods tellectual property royalty : livery potential HYLOGICA OND BA pODIES
Slide 15: Funding and collaboration for projects
ived $2.2 million of funding from a nt for this project signed with the University. of ee targets are being screened for Phylomer® ockers n cell assays SZ : e tested atthe University of M | ty ik the ourne in evant animal RA.disease models HYLOGICA FOND BNIB ODIES
Slide 16: Drug Development Portfolio
ug Development Portfolio HYLOGICA OND BA pODIES
Slide 17: Biotech Comparators
al Biotech Comparators ples where biotechnology drug aseavery Rams HYLOGICA FOND BNIB ODIES
Slide 18: Treat unmet need markets
treat unmet need markets: treatment (PYC35B).and RA ited new drugs can be developed as these drugs ness mode focused on early revenue and with Pharma and biotec! illion dollar market) — al pric d with significant uU MD BAT ODIES
Slide 19: Phylogica Limited
hylogica Limited yond Antibedies HYLOGICA MD BAT ODIES